Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.

Employees

6,545

Sector

Personal Products

Calendar

2025-01-08 - Baader Swiss Equities Conference

More about the company

Quotes

Date	Price	Change	Volume
24-12-11	90.17 CHF	+0.41%	86,254
24-12-10	89.80 CHF	+1.00%	295,779
24-12-09	88.91 CHF	+1.30%	216,557
24-12-06	87.77 CHF	-2.00%	212,044
24-12-05	89.56 CHF	+0.13%	157,093

Delayed Quote Swiss Exchange, December 11, 2024 at 09:16 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart GALDERMA-GROUP-AG

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

101.81USD

Average target price

108.65USD

Spread / Average Target

+6.72%

Consensus

Profit revisions

estimates-change-chart GALDERMA-GROUP-AG

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GALDERMA-GROUP-AG

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:19:59 2024-12-11 am EST			5-day change	1st Jan Change
90.17 ^CHF	+0.41%		+0.82%	0.00%

Nov. 21	Global markets live: Nvidia, Snowflake, Reddit, Target, Comcast...
Nov. 21	Several major shareholders, including EQT, sell shares in Galderma	FW

Capitalization	24.19B 23.02B 21.33B 18.97B 34.25B 2,053B 37.96B 266B 98.06B 843B 90.8B 88.84B 3,678B	P/E ratio 2024 *	126x	P/E ratio 2025 *	51.4x
Enterprise value	26.47B 25.2B 23.35B 20.77B 37.49B 2,247B 41.55B 291B 107B 923B 99.39B 97.25B 4,026B	EV / Sales 2024 *	5.96x	EV / Sales 2025 *	5.22x
Free-Float	-	Yield 2024 *	0.08%	Yield 2025 *	0.3%

Global markets live: Nvidia, Snowflake, Reddit, Target, Comcast...	Nov. 21
Several major shareholders, including EQT, sell shares in Galderma	Nov. 21	FW
Galderma's Shareholders to Offload Minority Stake in Upsized Offering	Nov. 20	MT
L'Oréal Prices EUR1.25 Billion Bond Offering	Oct. 30	MT
L'Oréal: bond placement for 1.25 billion euros	Oct. 30	CF
Musk on top of Wall Street	Oct. 25
Busy Earnings Day Boosts Swiss Stocks	Oct. 24	MT
Galderma Group AG, Q3 2024 Sales/ Trading Statement Call, Oct 24, 2024	Oct. 24
Galderma posts 9.2% sales growth in first nine months of 2024	Oct. 24	RE
Galderma Posts Higher Nine-month Net Sales, Narrows FY24 Sales Guidance	Oct. 24	MT
Galderma Group AG Revises Earnings Guidance for the Year 2024	Oct. 24	CI
Galderma Announces New Phase III Data from the READY-4 Clinical Trial	Oct. 21	CI
IPO: The best and worst IPOs of 2024	Oct. 15

RBC Capital Lifts Price Target on Galderma Group, Maintains Outperform Recommendation	Sep. 24	MT
JP Morgan Starts Galderma Coverage at Overweight	Aug. 09	MT
Bank Vontobel Begins Galderma Coverage with Buy Rating	Jul. 03	MT

Galderma Group AG Stock

Equities

GALD

CH1335392721

Personal Products

Valuation: Galderma Group AG

Chart: Galderma Group AG

Latest news: Galderma Group AG

Last Transcript: Galderma Group AG

Analysts' recommendations: Galderma Group AG

Press Releases: Galderma Group AG

News in other languages: Galderma Group AG

Quotes and Performance

Course Extremes

Cosmetics & Perfumes

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis	Nov. 28	BU
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation	Nov. 04	BU
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends	Oct. 25	BU
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance	Oct. 24	BU
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)	Oct. 21	BU

Wall Street vacille, l'Europe s'éparpille, la Chine scintille	Dec. 10
Avis d'analystes du jour : L'Oréal, Unibail, TotalEnergies, Schneider, Nexans, Galderma, Amundi, Accor...	Dec. 10
Aktien Schweiz Eröffnung: Knappes Plus - Gewinnmitnahmen bei Swiss Life	Dec. 03
Le CAC40 fait de la résistance	Dec. 03
Avis d'analystes du jour : Kering, Hermès, Michelin, UCB, Euroapi, Forvia, Galderma, Ipsen...	Dec. 03

1 day	+0.52%
1 week	+0.91%
1 month	+6.49%
3 months	+11.97%
6 months	+23.63%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GALDERMA GROUP AG	+0.52%	+0.91%	-	-	24.19B
L'ORÉAL	-0.59%	+3.03%	-22.64%	-17.86%	194B
KAO CORPORATION	+1.51%	+0.12%	+14.47%	+9.78%	20.07B
SHISEIDO COMPANY, LIMITED	-0.69%	+3.46%	-27.14%	-58.78%	7.39B
COTY INC.	+0.52%	+3.20%	-33.30%	-23.65%	6.74B
PROYA COSMETICS CO.,LTD.	+3.00%	+1.47%	-9.47%	-12.29%	5.07B
AMOREPACIFIC CORPORATION	+7.24%	-2.56%	-14.91%	-40.39%	4.6B
INTERPARFUMS, INC.	+0.76%	+0.85%	+5.05%	+43.39%	4.43B
NATURA &CO HOLDING S.A.	+5.95%	+0.77%	-15.52%	-43.72%	3.31B
INTERPARFUMS	+0.12%	+3.02%	-10.98%	-21.80%	3.26B
Average	+1.82%	+1.86%	-12.72%	-18.37%	27.31B
Weighted average by Cap.	+0.02%	+3.66%	-18.92%	-16.61%

	2024 *	2025 *
Net sales	4.44B 4.23B 3.92B 3.49B 6.29B 377B 6.97B 48.81B 18.02B 155B 16.68B 16.32B 676B	4.98B 4.74B 4.4B 3.91B 7.06B 423B 7.82B 54.74B 20.21B 174B 18.71B 18.31B 758B
Net income	226M 215M 199M 177M 320M 19.17B 355M 2.48B 916M 7.87B 848M 830M 34.35B	494M 470M 435M 387M 699M 41.88B 775M 5.42B 2B 17.2B 1.85B 1.81B 75.05B
Net Debt	2.29B 2.18B 2.02B 1.8B 3.24B 194B 3.59B 25.13B 9.28B 79.74B 8.59B 8.41B 348B	1.82B 1.73B 1.6B 1.42B 2.57B 154B 2.85B 19.95B 7.36B 63.28B 6.82B 6.67B 276B